Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

NCT04780568 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions

DRUG: Osimertinib
DRUG: Tegavivint
PROCEDURE: Echocardiography Test
PROCEDURE: Multigated Acquisition Scan
PROCEDURE: Computed Tomography
PROCEDURE: FDG-Positron Emission Tomography
PROCEDURE: Biospecimen Collection

Sponsor

Ohio State University Comprehensive Cancer Center